Compass Therapeutics shares plummeted after the FDA recommended a survival benefit trial for its cancer drug tovecimig before BLA submission, a requirement the company disputes. This significantly delays the drug's path to market and raises substantial uncertainty about its future commercialization, leading to a sharp sell-off.
Compass Therapeutics (CMPX) experienced a massive sell-off after the FDA recommended a survival benefit trial for its lead cancer drug, tovecimig, before it can submit a Biologics License Application (BLA). This is a critical setback because the company believes a new trial is not warranted, indicating a significant disagreement with the regulatory body. The FDA's demand introduces substantial delays and increased costs for CMPX, pushing back potential revenue generation and raising questions about the drug's ultimate approval. This news is a major negative catalyst for CMPX, as reflected in its stock price cratering to a 52-week low, and signals a long-term challenge for the company's pipeline and financial outlook.